WO1994016725A1 - Vaccin vivant contre la coccidiose - Google Patents

Vaccin vivant contre la coccidiose Download PDF

Info

Publication number
WO1994016725A1
WO1994016725A1 PCT/US1994/000075 US9400075W WO9416725A1 WO 1994016725 A1 WO1994016725 A1 WO 1994016725A1 US 9400075 W US9400075 W US 9400075W WO 9416725 A1 WO9416725 A1 WO 9416725A1
Authority
WO
WIPO (PCT)
Prior art keywords
vaccine
eimeria
species
administered
oocysts
Prior art date
Application number
PCT/US1994/000075
Other languages
English (en)
Inventor
Dennis M. Schmatz
James L. Cox
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Priority to AU59898/94A priority Critical patent/AU5989894A/en
Publication of WO1994016725A1 publication Critical patent/WO1994016725A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/012—Coccidia antigens

Definitions

  • infective stages of cocci dial organisms such as sporulated oocysts
  • infective stages of cocci dial organisms can be administered to neonatal fowl to induce immunity against coccidiosis.
  • administration of such "wild-type" organisms must be followed by the administration of anticoccidial agents to prevent the outbreak of coccidiosis by the infective organisms.
  • the administration of such infective strains requires that the fowl, preferably chickens, be maintained on litter to provide for a constant level of reinfection to stimulate lasting immunity. This technique also suffers failure when too many or too few oocysts are administered.
  • Attenuated strains are capable of conferring immunity and precocious strains are capable of developing into the next stage, however, the reduced level of infectivity of the attenuated strains, combined with the shortened development period of the parasite induces immunity without pathology and thus the host will not suffer ill effects from the vaccination.
  • attenuated precocious strains because they are less infective must be administered at higher levels, based on the number of oocysts administered, and it is recommended that vaccination with sporulated oocysts not take place earlier than three days after birth. See U.S. Patents 4,438,097 to Shirley and 5,055,292 to McDonald, et al
  • the instant invention provides for the full immunization of fowl against coccidiosis by the oral administration of live sporulated oocysts of attenuated precocious strains of Eimeria at day one of age without the subsequent administration of anticoccidial agents.
  • a still further object is to describe formulations and methods to administer the oocysts to such fowl. Further objects will become apparent from a reading of the following description.
  • This invention is concerned with the administration of live, attenuated, precocious strains of coccidial organisms, in particular strains of Eimeria. to newly hatched fowl, in particular, chickens, but also turkey, ducks, quail and the like.
  • the vaccine may be univalent, with a single species of Eimeria in the vaccine, but preferably a polyvalent vaccine is employed containing from two to all seven of the common species of Eimeria. viz E. necatrix. E. aservulina, E. brunetti. E. mitis. E. mivati. E. praecox and E. tenella.
  • the particular content of the polyvalent vaccine may be adjusted to contain different species depending on local conditions and the prevalence of particular species in certain areas.
  • the most preferred vaccine contains all seven precocious species of Eimeria in the live attenuated form of sporulated oocysts.
  • the vaccine is administered to newly hatched chicks and preferably within one to two days of hatching. Following typical husbandry techniques found in modern hatcheries, the vaccine is most preferably administered when the chicks are first processed in a process which administers other materials to the chick, such as other vaccines, for example Marek's disease, and perhaps vitamins and nutrients. During the process the chicks are also usually debeaked.
  • the instant vaccine finds its most preferred industrial utility when administered along with other administered materials such that the chicks are only handled once. However, on farms with a smaller scale of operations, it will not be uncommon to administer the instant vaccine as a single administration without the concurrent administration of other materials and the simultaneous debeaking of the chicks.
  • the instant vaccine is generally administered as an aqueous suspension of the attenuated, precocious oocysts of Eimeria.
  • the aqueous suspension can contain various suspending agents, thickeners and preservatives to assure an even distribution of the oocysts throughout the suspension.
  • the dosages of the attenuated precocious oocysts ranges from about 5 to about 1000 oocysts per bird for each of the Eimeria species included in the vaccine since one species will not necessarily confer immunity against a challenge from another species.
  • a more preferred dosage will be from about 10 to 500 oocysts per species per bird, most preferably between 10 and 100 oocysts per species per bird.
  • the precise number of each species present in the polyvalent vaccine will vary depending on the specific level of infectivity of each species and it will be normal to have a vaccine with different numbers of each species to reflect such different characteristics of each species.
  • the vaccine is administered in a total volume of from about 0.1 to 1.0 ml, preferably about 0.25 to 0.50 ml.
  • the vaccine discussed in McDonald, et al has been developed into a commercial product for chickens under the trademark of PARACOX. This is a combination of all seven principal species of Eimeria in an aqueous suspension. The product is labeled for administration to chickens from 5 to 9 days of age. Administration to chickens younger than 5 days is not recommended.
  • the fourth group of birds was fed a ration containing 60 ppm of salinomycin to suppress coccidial development; from Day 27 on these birds received unmedicated feed. Temperature and humidity were maintained at comfortable levels appropriate for the age of the chickens. When the birds were 27 days old, birds were taken from each pen, weighed and placed in battery cages. The birds remained on the same rations in cages as when on the floor. These birds were challenged with 10,000 sporulated oocysts of field strain of Eimeria tenella per bird after 24 hours in the cages. Feces were collected for Days 4 to 6 inclusive after challenge. The birds were weighed and necropsied at 8 days after challenge.
  • the birds remaining in the floor-pens were weighed and challenged with 30,000 sporulated oocysts of Eimeria maxima per bird on Day 28. Samples of feces were collected from each pen at intervals to monitor oocyst output from the challenged birds. A sample of birds were taken at 7 days after challenge to determine lesion scores and all the birds were weighed. The results of the study show that vaccinated birds were protected from the harmful effects of challenge (Tables 1 and 2) and that the birds showed significant weight gain and feed efficiency improvements over the unvaccinated birds. Table 3, 4 and 5 show the live weight of the birds, the average feed conversion per bird and the average feed efficiency per bird.
  • Treatments were replicated eight times. Average Live Weight, Feed Conversion and, Feed Efficiency of birds vaccinated with 0.20X, IX or 5X level of PARACOX administered once by gavage on Day 0 and compared with unvaccinated birds fed 60 ppm Salinomycin up to Day 27 and unmedicated feed thereafter.
  • Treatments were replicated eight times. Average Live Weight, Feed conversion and, Feed Efficiency of birds vaccinated with 0.20X, IX or 5X level of PARACOX administered once by gavage on Day 0 and compared with unvaccinated birds fed 60 ppm Salinomycin up to Day 27 and unmedicated feed thereafter. Birds of all treatment groups were challenged on Day 28 with 30,000 sporulated oocysts of Eimeria maxima per bird via feed. 0
  • Treatments were replicated eight times. Average Live Weight, Feed Conversion and, Feed Efficiency of birds vaccinated with 0.20X, IX or 5X level of PARACOX administered once by gavage on Day 0 and compared with unvaccinated birds fed 60 ppm Salinomycin up to Day 27 and unmedicated feed thereafter. Birds of all treatment groups were challenged on Day 28 with 30,000 sporulated oocysts of Eimeria maxiuma per bird via feed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Fodder In General (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Des oocytes sporulés vivants sont administrés à des poussins d'un jour afin de les immuniser contre la coccidiose sans qu'il soit nécessaire de recourir à une thérapie anticoccidique supplémentaire.
PCT/US1994/000075 1993-01-19 1994-01-03 Vaccin vivant contre la coccidiose WO1994016725A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU59898/94A AU5989894A (en) 1993-01-19 1994-01-03 Live coccidiosis vaccine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US634993A 1993-01-19 1993-01-19
US006,349 1993-01-19

Publications (1)

Publication Number Publication Date
WO1994016725A1 true WO1994016725A1 (fr) 1994-08-04

Family

ID=21720465

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/000075 WO1994016725A1 (fr) 1993-01-19 1994-01-03 Vaccin vivant contre la coccidiose

Country Status (3)

Country Link
AU (1) AU5989894A (fr)
WO (1) WO1994016725A1 (fr)
ZA (1) ZA94336B (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040234A1 (fr) * 1995-06-07 1996-12-19 Pfizer Inc. Vaccination in ovo contre la coccidiose
WO1996040233A1 (fr) * 1995-06-07 1996-12-19 Pfizer Inc. Vaccination in ovo contre la coccidiose
WO1999050387A1 (fr) * 1998-03-30 1999-10-07 Eimeria Pty. Limited Modalites de vaccination
WO2001034187A2 (fr) * 1999-11-08 2001-05-17 Novus International, Inc. Preparation et methode destinees a la prevention de la coccidiose
US6344340B1 (en) 1999-03-01 2002-02-05 Novus International, Inc. Viability assay for sporocyst-forming protozoa
WO2003072044A2 (fr) * 2002-02-26 2003-09-04 Wyeth Selection de souches eimeria du poulet au moyen de sporozoites extra-intestinaux
US6627205B2 (en) 1997-12-01 2003-09-30 Pfizer Incorporated Ovo vaccination against coccidiosis
US6733759B2 (en) * 1995-06-07 2004-05-11 Novus International, Inc. Nutrient formulation and process for enhancing the health, livability, cumulative weight gain or feed efficiency in poultry and other animals
US6908620B2 (en) * 2002-12-09 2005-06-21 University Of Georgia Research Foundation, Inc. Coccidial vaccine and methods of making and using same
US6984378B1 (en) 1999-02-26 2006-01-10 Pfizer, Inc. Method for the purification, recovery, and sporulation of cysts and oocysts
US7166290B2 (en) 2001-08-30 2007-01-23 Embrex, Inc. Methods for producing oocysts
US7247309B2 (en) * 1999-12-21 2007-07-24 Intervet International B.V. Coccidiosis vaccines
US7250286B2 (en) 2002-05-21 2007-07-31 Schering-Plough Corporation Methods for the in vitro culture of Sporozoea sp. and uses thereof
US7354593B2 (en) 2002-12-09 2008-04-08 Merial Limited Coccidial vaccine and methods of making and using same
US7846685B2 (en) 2000-11-08 2010-12-07 Novus International, Inc. Methods and compositions for the control of coccidiosis
US10781418B2 (en) 2017-01-24 2020-09-22 Huvepharma, Inc. Antibiotic-free compositions for the prevention or control of coccidiosis
WO2023170057A1 (fr) * 2022-03-08 2023-09-14 Hipra Scientific, S.L.U. Compositions vaccinales in ovo contre la coccidiose

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438097A (en) * 1980-09-05 1984-03-20 National Research Development Corporation Coccidiosis vaccines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438097A (en) * 1980-09-05 1984-03-20 National Research Development Corporation Coccidiosis vaccines

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ABSTRACT AVIAN PATHOLOGY, Volume 18, No. 2, issued 1989, BEDRNIK et al., "Field Vaccination of Broilers Against Coccidiosis", Biodid number 88062625, pages 255-264. *
AVIAN PATHOLOGY, Volume 15, issued 1986, LONG et al., "Immunisation of Young Broiler Chickens with Low Level Infections of Eimeria Tenella, E, Acervulina or E. Maxima", pages 271-278. *
SECOND ASIAN/PACIFIC POULTRY HEALTH CONFERENCE, PROCEEDINGS 112, issued 23-25 September 1988, SHIRLEY, "Control of Coccidiosis with Vaccines", pages 129-157. *

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040233A1 (fr) * 1995-06-07 1996-12-19 Pfizer Inc. Vaccination in ovo contre la coccidiose
AU694872B2 (en) * 1995-06-07 1998-07-30 Pfizer Inc. in ovo vaccination against coccidiosis
US7018640B2 (en) 1995-06-07 2006-03-28 Pfizer Incorporated In ovo vaccination against coccidiosis
WO1996040234A1 (fr) * 1995-06-07 1996-12-19 Pfizer Inc. Vaccination in ovo contre la coccidiose
US6495146B1 (en) 1995-06-07 2002-12-17 Pfizer Incorporated In ovo vaccination against coccidiosis
US6500438B2 (en) * 1995-06-07 2002-12-31 Pfizer Incorporated In ovo vaccination against coccidiosis
US6733759B2 (en) * 1995-06-07 2004-05-11 Novus International, Inc. Nutrient formulation and process for enhancing the health, livability, cumulative weight gain or feed efficiency in poultry and other animals
US6627205B2 (en) 1997-12-01 2003-09-30 Pfizer Incorporated Ovo vaccination against coccidiosis
WO1999050387A1 (fr) * 1998-03-30 1999-10-07 Eimeria Pty. Limited Modalites de vaccination
US7211265B2 (en) 1998-03-30 2007-05-01 Eimeria Pty. Limited Vaccination modalities
US6984378B1 (en) 1999-02-26 2006-01-10 Pfizer, Inc. Method for the purification, recovery, and sporulation of cysts and oocysts
US7229615B2 (en) 1999-02-26 2007-06-12 Pfizer, Inc. Method for the purification, recovery, and sporulation of cysts and oocysts
US6344340B1 (en) 1999-03-01 2002-02-05 Novus International, Inc. Viability assay for sporocyst-forming protozoa
WO2001034187A3 (fr) * 1999-11-08 2002-03-21 Novus Int Inc Preparation et methode destinees a la prevention de la coccidiose
WO2001034187A2 (fr) * 1999-11-08 2001-05-17 Novus International, Inc. Preparation et methode destinees a la prevention de la coccidiose
US7247309B2 (en) * 1999-12-21 2007-07-24 Intervet International B.V. Coccidiosis vaccines
US7846685B2 (en) 2000-11-08 2010-12-07 Novus International, Inc. Methods and compositions for the control of coccidiosis
US9107865B2 (en) 2001-08-30 2015-08-18 Zoetis Services Llc Methods for producing oocysts
US7166290B2 (en) 2001-08-30 2007-01-23 Embrex, Inc. Methods for producing oocysts
WO2003072044A3 (fr) * 2002-02-26 2004-03-25 Wyeth Corp Selection de souches eimeria du poulet au moyen de sporozoites extra-intestinaux
US6998126B2 (en) 2002-02-26 2006-02-14 Wyeth Selection of poultry Eimeria strains through extra-intestinal sporozoites
WO2003072044A2 (fr) * 2002-02-26 2003-09-04 Wyeth Selection de souches eimeria du poulet au moyen de sporozoites extra-intestinaux
US7816118B2 (en) 2002-05-21 2010-10-19 Schering-Plough Corporation Methods for the in vitro culture of Sporozoea sp. and uses thereof
US7250286B2 (en) 2002-05-21 2007-07-31 Schering-Plough Corporation Methods for the in vitro culture of Sporozoea sp. and uses thereof
US6998127B2 (en) 2002-12-09 2006-02-14 Merial Limited Coccidial vaccine and methods of making and using same
US7354593B2 (en) 2002-12-09 2008-04-08 Merial Limited Coccidial vaccine and methods of making and using same
US6908620B2 (en) * 2002-12-09 2005-06-21 University Of Georgia Research Foundation, Inc. Coccidial vaccine and methods of making and using same
US10781418B2 (en) 2017-01-24 2020-09-22 Huvepharma, Inc. Antibiotic-free compositions for the prevention or control of coccidiosis
US11692164B2 (en) 2017-01-24 2023-07-04 Huvepharma Inc. Antibiotic-free compositions for the prevention or control of coccidiosis
WO2023170057A1 (fr) * 2022-03-08 2023-09-14 Hipra Scientific, S.L.U. Compositions vaccinales in ovo contre la coccidiose

Also Published As

Publication number Publication date
AU5989894A (en) 1994-08-15
ZA94336B (en) 1994-08-26

Similar Documents

Publication Publication Date Title
Chapman Practical use of vaccines for the control of coccidiosis in the chicken
EP0047662B1 (fr) Vaccins contre la coccidiose
EP0256878B1 (fr) Vaccins
WO1994016725A1 (fr) Vaccin vivant contre la coccidiose
US6495146B1 (en) In ovo vaccination against coccidiosis
EP1569687B1 (fr) Vaccin coccidial et ses procedes de preparation et d'utilisation
Weber et al. Immunization of broiler chicks by in ovo injection of Eimeria tenella sporozoites, sporocysts, or oocysts
US10758601B2 (en) Eimeria vaccine with improved efficacy
Waldenstedt et al. Comparison between a live, attenuated anticoccidial vaccine and an anticoccidial ionophore, on performance of broilers raised with or without a growth promoter, in an initially Eimeria-free environment
Williams et al. The origins and biological significance of the coccidial lesions that occur in chickens vaccinated with a live attenuated anticoccidial vaccine
Shirley et al. Live attenuated coccidiosis vaccine: selection of a second precocious line of Eimeria maxima
US6627205B2 (en) Ovo vaccination against coccidiosis
US7879342B2 (en) Vaccine adjuvant and making and using the same
Price et al. Examination of a novel practical poultry management method to enhance the effect of live Eimeria vaccination for conventionally housed replacement layer pullets
Williams et al. Anticoccidial vaccination of broiler chickens in various management programmes: relationship between oocyst accumulation in litter and the development of protective immunity
EP0258045B1 (fr) Méthode pour modifier la qualité d'animaux
EP1476558B1 (fr) Selection de souches eimeria du poulet au moyen de sporozoites extra-intestinaux
Gore et al. Attenuation of Eimeria necatrix and E. tenella of US origin by serial embryo passage
Norton Eimeria colchici sp. nov.(Protozoa: Eimeriidae), the cause of cecal coccidiosis in English covert pheasants
EP1742656B1 (fr) Nouvel extrait de peau de cacahuète utilisé comme adjuvant de vaccin
US6767546B1 (en) Use of echinacea as a feed additive to enhance protection against coccidiosis
Bedrnik et al. Field vaccination of broilers against coccidiosis
EP0069407B1 (fr) Méthode d'immunisation de porcs contre la maladie d'Aujeszky
Fuller et al. Immunization of chukar partridges against coccidia (Eimeria kofoidi and Eimeria legionensis) with low doses of live oocysts
Abdul Rasheed Assessment of the Level of Protection against Coccidiosis in Broiler Breeders Conferred by a Live Anticoccidial Vaccine, and its Influence on Early Growth and Development.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR BY CA CN CZ FI HU JP KR KZ LK LV MG MN MW NO NZ PL RO RU SD SK UA US UZ

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA